RBN012759 - CAS# 2360851-29-0


Catalog No. Size PriceQuantity
M16345-C Contact sales@xcessbio.com for quotation $100

Description

RBN012759 is a potent and selective PARP14 inhibitor which decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. RBN012759 inhibits PARP14 with a biochemical half-maximal inhibitory concentration of 0.003 μM, exhibits >300-fold selectivity over all PARP family members, and its profile enables further study of PARP14 biology and disease association both in vitro and in vivo. Inhibition of PARP14 with RBN012759 reverses IL-4-driven protumor gene expression in macrophages and induces an inflammatory mRNA signature similar to that induced by immune checkpoint inhibitor therapy in primary human tumor explants.

Product information

CAS Number: 2360851-29-0

Molecular Weight: 378.46

Formula: C19H23FN2O3S

Chemical Name: 7-(cyclopropylmethoxy)-5-fluoro-2-({[(1r,4r)-4-hydroxycyclohexyl]sulfanyl}methyl)-3,4-dihydroquinazolin-4-one

Smiles: O[C@@H]1CC[C@H](CC1)SCC1NC(=O)C2C(F)=CC(=CC=2N=1)OCC1CC1

InChiKey: NKZDEFKPZSLQRF-MQMHXKEQSA-N

InChi: InChI=1S/C19H23FN2O3S/c20-15-7-13(25-9-11-1-2-11)8-16-18(15)19(24)22-17(21-16)10-26-14-5-3-12(23)4-6-14/h7-8,11-12,14,23H,1-6,9-10H2,(H,21,22,24)/t12-,14-

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed